NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks ae kusterer, one thing that a lot of NWBO longs are failing to grasp or understand, is that now when Dr. Linda Liau speaks about DCVax-L (DC Vaccine) alone, she actually means DCVax-L along with poly-ICLC.

This is because poly-ICLC has been added as a component to the DCVax-L formulation as an in vivo maturation agent, that will maturate and hyperactivate the dendritic cells in situ.

There are no current DCVax-L clinical trials, or future planned DCVax-L clinical trials, that does not include poly-ICLC as an in vivo maturation agent.

The 2 (DCVax-L and poly-ICLC) are not mixed together into 1 vaccine, but are co-administered, at the same time. The DCVax-L is administered intradermally, and the poly-ICLC is administered intramuscarly, at the same time. Poly-ICLC is not referred to as an adjuvant treatment. The 2 shots work together, and are collectively referrred to as DCVax: